Brokerages Anticipate Eyegate Pharmaceuticals, Inc. (EYEG) Will Announce Quarterly Sales of $180,000.00
Equities analysts expect Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to post $180,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Eyegate Pharmaceuticals’ earnings, with the highest sales estimate coming in at $200,000.00 and the lowest estimate coming in at $160,000.00. Eyegate Pharmaceuticals posted sales of $270,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The business is scheduled to report its next earnings results on Tuesday, November 7th.
According to Zacks, analysts expect that Eyegate Pharmaceuticals will report full year sales of $180,000.00 for the current financial year, with estimates ranging from $330,000.00 to $1.08 million. For the next financial year, analysts expect that the company will post sales of $7.88 million per share. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Eyegate Pharmaceuticals.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Eyegate Pharmaceuticals in a research report on Wednesday, June 14th.
Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) traded up 5.41% during trading on Friday, reaching $1.17. 112,414 shares of the company’s stock were exchanged. Eyegate Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $3.90. The firm’s market capitalization is $20.13 million. The company has a 50 day moving average of $1.18 and a 200 day moving average of $1.18.
An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. lifted its stake in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 247,319 shares of the specialty pharmaceutical company’s stock after buying an additional 1,988 shares during the quarter. Vanguard Group Inc. owned about 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.99% of the company’s stock.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.